SnapShot: The hallmarks of cancer treatment.

For decades, the standard weapon against cancer was traditional chemotherapy. These foundational drugs are essentially blunt instruments. They are highly effective at destroying cancer cells, but their use is severely restricted because they are deeply toxic to the rest of the healthy body. Today, cancer care has evolved toward a much more precise approach. Doctors now use molecular profiling to look at the unique genetic makeup of a tumor and choose treatments tailored to those specific mutations.

This modern toolkit includes targeted therapies that exploit specific vulnerabilities in cancer cells, alongside advanced immune treatments. Scientists have even engineered specialized tools like CAR-T therapy, which modifies a patient's own immune cells to attack tumors, and ADCs, or antibody-drug conjugates, which act like guided missiles delivering medication directly to the disease. However, these breakthroughs still face a massive hurdle. Tumors are highly adaptable. Targeted therapies often wipe out the bulk of a tumor but leave behind resistant cells that eventually multiply. Similarly, immune treatments can fail if the tumor mutates and sheds the specific markers the immune system is trained to find.

To move forward, scientists realize they have to stop treating tumors as static targets. The ongoing challenge for researchers is that cancer therapies themselves often push tumors to evolve and develop resistance.